

# Linda S May-Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10901031/publications.pdf>

Version: 2024-02-01

9  
papers

173  
citations

1307594

7  
h-index

1588992

8  
g-index

11  
all docs

11  
docs citations

11  
times ranked

245  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modification by isolevuglandins, highly reactive $\beta$ -ketoaldehydes, deleteriously alters high-density lipoprotein structure and function. <i>Journal of Biological Chemistry</i> , 2018, 293, 9176-9187.	3.4	44
2	Administration of N-Acyl-Phosphatidylethanolamine Expressing Bacteria to Low Density Lipoprotein Receptor <sup>-/-</sup> Mice Improves Indices of Cardiometabolic Disease. <i>Scientific Reports</i> , 2019, 9, 420.	3.3	28
3	Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions. , 2020, 205, 107418.		27
4	Engineering the gut microbiota to treat chronic diseases. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 7657-7671.	3.6	19
5	Modified sites and functional consequences of 4-oxo-2-nonenal adducts in HDL that are elevated in familial hypercholesterolemia. <i>Journal of Biological Chemistry</i> , 2019, 294, 19022-19033.	3.4	16
6	Myeloperoxidase-induced modification of HDL by isolevuglandins inhibits paraoxonase-1 activity. <i>Journal of Biological Chemistry</i> , 2021, 297, 101019.	3.4	13
7	Isolevuglandins and cardiovascular disease. <i>Prostaglandins and Other Lipid Mediators</i> , 2018, 139, 29-35.	1.9	12
8	Kidney injury-mediated disruption of intestinal lymphatics involves dicarbonyl-modified lipoproteins. <i>Kidney International</i> , 2021, 100, 585-596.	5.2	11
9	Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma. <i>Journal of Clinical Lipidology</i> , 2020, 14, 293-296.	1.5	2